News and Announcements
Novogen CEO interviewed on CommSec
- Published July 04, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
CommSec released an interview today as part of its Executive Series, featuring Executive Director and CEO, Dr James Garner.
KEY TAKEAWAYS:
- Tom Piotrowski talks with Dr Garner about Novogen’s business model and the way it is being used to bring to market the best of available cancer treatments.
- Providing an overview of Novogen’s pipeline.
Dr Garner talked about the next steps for the Company’s lead candidate GDC-0084, a drug to treat Glioblastoma Multiforme. GDC-0084 was licenced from Genentech, and showed great promise in a Phase I clinical trial. A Phase II clinical trial is expected will start later this year.